Cargando…

Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern

SARS-CoV-2 infection and/or vaccination elicit a broad range of neutralizing antibody responses against the different variants of concern (VOC). We established a new variant-adapted surrogate virus neutralization test (sVNT) and assessed the neutralization activity against the ancestral B.1 (WT) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos da Silva, Eveline, Servais, Jean-Yves, Kohnen, Michel, Arendt, Vic, Staub, Therese, Krüger, Rejko, Fagherazzi, Guy, Wilmes, Paul, Hübschen, Judith M., Ollert, Markus, Perez-Bercoff, Danielle, Seguin-Devaux, Carole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573711/
https://www.ncbi.nlm.nih.gov/pubmed/37834413
http://dx.doi.org/10.3390/ijms241914965
_version_ 1785120527286796288
author Santos da Silva, Eveline
Servais, Jean-Yves
Kohnen, Michel
Arendt, Vic
Staub, Therese
Krüger, Rejko
Fagherazzi, Guy
Wilmes, Paul
Hübschen, Judith M.
Ollert, Markus
Perez-Bercoff, Danielle
Seguin-Devaux, Carole
author_facet Santos da Silva, Eveline
Servais, Jean-Yves
Kohnen, Michel
Arendt, Vic
Staub, Therese
Krüger, Rejko
Fagherazzi, Guy
Wilmes, Paul
Hübschen, Judith M.
Ollert, Markus
Perez-Bercoff, Danielle
Seguin-Devaux, Carole
author_sort Santos da Silva, Eveline
collection PubMed
description SARS-CoV-2 infection and/or vaccination elicit a broad range of neutralizing antibody responses against the different variants of concern (VOC). We established a new variant-adapted surrogate virus neutralization test (sVNT) and assessed the neutralization activity against the ancestral B.1 (WT) and VOC Delta, Omicron BA.1, BA.2, and BA.5. Analytical performances were compared against the respective VOC to the reference virus neutralization test (VNT) and two CE-IVD labeled kits using three different cohorts collected during the COVID-19 waves. Correlation analyses showed moderate to strong correlation for Omicron sub-variants (Spearman’s r = 0.7081 for BA.1, r = 0.7205 for BA.2, and r = 0.6042 for BA.5), and for WT (r = 0.8458) and Delta-sVNT (r = 0.8158), respectively. Comparison of the WT-sVNT performance with two CE-IVD kits, the “Icosagen SARS-CoV-2 Neutralizing Antibody ELISA kit” and the “Genscript cPass, kit” revealed an overall good correlation ranging from 0.8673 to −0.8773 and a midway profile between both commercial kits with 87.76% sensitivity and 90.48% clinical specificity. The BA.2-sVNT performance was similar to the BA.2 Genscript test. Finally, a correlation analysis revealed a strong association (r = 0.8583) between BA.5-sVNT and VNT sVNT using a double-vaccinated cohort (n = 100) and an Omicron-breakthrough infection cohort (n = 91). In conclusion, the sVNT allows for the efficient prediction of immune protection against the various VOCs.
format Online
Article
Text
id pubmed-10573711
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105737112023-10-14 Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern Santos da Silva, Eveline Servais, Jean-Yves Kohnen, Michel Arendt, Vic Staub, Therese Krüger, Rejko Fagherazzi, Guy Wilmes, Paul Hübschen, Judith M. Ollert, Markus Perez-Bercoff, Danielle Seguin-Devaux, Carole Int J Mol Sci Article SARS-CoV-2 infection and/or vaccination elicit a broad range of neutralizing antibody responses against the different variants of concern (VOC). We established a new variant-adapted surrogate virus neutralization test (sVNT) and assessed the neutralization activity against the ancestral B.1 (WT) and VOC Delta, Omicron BA.1, BA.2, and BA.5. Analytical performances were compared against the respective VOC to the reference virus neutralization test (VNT) and two CE-IVD labeled kits using three different cohorts collected during the COVID-19 waves. Correlation analyses showed moderate to strong correlation for Omicron sub-variants (Spearman’s r = 0.7081 for BA.1, r = 0.7205 for BA.2, and r = 0.6042 for BA.5), and for WT (r = 0.8458) and Delta-sVNT (r = 0.8158), respectively. Comparison of the WT-sVNT performance with two CE-IVD kits, the “Icosagen SARS-CoV-2 Neutralizing Antibody ELISA kit” and the “Genscript cPass, kit” revealed an overall good correlation ranging from 0.8673 to −0.8773 and a midway profile between both commercial kits with 87.76% sensitivity and 90.48% clinical specificity. The BA.2-sVNT performance was similar to the BA.2 Genscript test. Finally, a correlation analysis revealed a strong association (r = 0.8583) between BA.5-sVNT and VNT sVNT using a double-vaccinated cohort (n = 100) and an Omicron-breakthrough infection cohort (n = 91). In conclusion, the sVNT allows for the efficient prediction of immune protection against the various VOCs. MDPI 2023-10-06 /pmc/articles/PMC10573711/ /pubmed/37834413 http://dx.doi.org/10.3390/ijms241914965 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Santos da Silva, Eveline
Servais, Jean-Yves
Kohnen, Michel
Arendt, Vic
Staub, Therese
Krüger, Rejko
Fagherazzi, Guy
Wilmes, Paul
Hübschen, Judith M.
Ollert, Markus
Perez-Bercoff, Danielle
Seguin-Devaux, Carole
Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern
title Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern
title_full Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern
title_fullStr Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern
title_full_unstemmed Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern
title_short Validation of a SARS-CoV-2 Surrogate Neutralization Test Detecting Neutralizing Antibodies against the Major Variants of Concern
title_sort validation of a sars-cov-2 surrogate neutralization test detecting neutralizing antibodies against the major variants of concern
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573711/
https://www.ncbi.nlm.nih.gov/pubmed/37834413
http://dx.doi.org/10.3390/ijms241914965
work_keys_str_mv AT santosdasilvaeveline validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern
AT servaisjeanyves validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern
AT kohnenmichel validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern
AT arendtvic validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern
AT staubtherese validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern
AT validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern
AT validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern
AT krugerrejko validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern
AT fagherazziguy validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern
AT wilmespaul validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern
AT hubschenjudithm validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern
AT ollertmarkus validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern
AT perezbercoffdanielle validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern
AT seguindevauxcarole validationofasarscov2surrogateneutralizationtestdetectingneutralizingantibodiesagainstthemajorvariantsofconcern